SNGX: Soligenix Inc Company Profile & Statistics

About

Soligenix, Inc. is a late-stage biopharmaceutical company focused on developing products to treat the life-threatening side effects of cancer treatments and serious gastrointestinal diseases where, as well as developing several biodefense vaccines and therapeutics. The Company operates in two reportable segments: BioTherapeutics and BioDefense. The BioTherapeutics business segment intends to develop orBec ? (oral beclomethasone dipropionate, or oral BDP) and other biotherapeutic products, including LPM TM Leuprolide. The BioDefense business segment intends to convert its ricin toxin vaccine and radiation injury programs from early stage development to advanced development and manufacturing. Soligenix, Inc, formerly known as DOR BioPharma, Inc, is headquartered in Princeton, New Jersey.

Info & Links

CEO

Christopher J. Schaber

Headquarters

29 EMMONS DRIVE, SUITE B-10
PRINCETON, NJ 08540, UNITED STATES

Auditor

Cherry Bekaert LLP

Share holders

112

Employees

Soligenix Inc Statistics

Valuation Measures

Market Capitalization²

7.88M

Enterprise Value

100.50K

Enterprise Value/EBITDA(ttm)

-0.01

Price to Earnings Ratio(ttm)

Price to Sales(ttm)

16.63

Price to Book(mrq)

1.21

Price to Cash(ytd)

Profitability

Gross Margin(ttm)

2.38%

Operating Margin(ttm)

-1473.38%

Profit Margin(ttm)

-18149.47%

Return on Equity(ttm)

-223.29%

Return on Invested Capital(ttm)

-377.21%

Return on Assets(ttm)

-74.18%

Income Statement

Revenue(ttm)

364.10K

Revenue Per Share(ttm)

0.15

Gross Profit(ttm)

23.30K

EBITDA(ttm)³

-7.86M

Net Income Available to Common(ttm)

-7.10M

Diluted EPS(ttm)

-7.53

Share Statistics

Beta (5Y Monthly)

1.79

52-Week Change

-73.11%

S&P 500 52-Week Change

23.87%

S&P 500 Member

Yes

Stock Optionable

Yes

Total Shares Outstanding¹

2.51M

Dividend Yield

0.00%

Float⁴

2.44M

% Held by Insiders

2.80%

% Held by Institutions

3.60%

Balance Sheet

Total Cash(mrq)

9.84M

Total Cash Per Share(mrq)

3.92

Total Debt(mrq)

2.06M

Total Debt/Equity(mrq)

34.70%

Current Ratio(mrq)

2.28%

Quick Ratio(mrq)

2.28%

Book Value Per Share(mrq)

2.59

Cash Flow

Operating Cash Flow Per Share(ytd)

-2.80

Free Cash Flow(ytd)

-6.17M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.

1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
2 Market Cap is calculated using total shares outstanding and the most recent share price.
3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.

SNGX

Soligenix Inc

Soligenix Inc Profile